Day One Biopharmaceuticals, Inc. financial data

Symbol
DAWN on Nasdaq
Industry
Pharmaceutical Preparations
Location
2000 Sierra Point Parkway, Suite 501, Brisbane, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Day One Biopharmaceuticals Holding Co LLC (to 5/26/2021)
Latest financial report
10-Q - Q2 2024 - Aug 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 844 %
Debt-to-equity 13.3 % +125%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 87.8M shares +0.9%
Common Stock, Shares, Outstanding 87.7M shares +0.83%
Entity Public Float 759M USD +8.68%
Common Stock, Value, Issued 9K USD 0%
Weighted Average Number of Shares Outstanding, Basic 87.1M shares +16.2%
Weighted Average Number of Shares Outstanding, Diluted 87.1M shares +16.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 203M USD +87.7%
General and Administrative Expense 97.2M USD +39.9%
Operating Income (Loss) -293M USD -64.8%
Nonoperating Income (Expense) 112M USD +3201%
Income Tax Expense (Benefit) 1.55M USD
Net Income (Loss) Attributable to Parent -4.41M USD +90.4%
Earnings Per Share, Basic -1.94 USD/shares +15.3%
Earnings Per Share, Diluted -1.94 USD/shares +15.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 240M USD +26.6%
Inventory, Net 151K USD
Other Assets, Current 322M USD +20.6%
Assets, Current 383M USD -14.8%
Property, Plant and Equipment, Net 196K USD +7.1%
Operating Lease, Right-of-Use Asset 164K USD -69.1%
Assets 400M USD -11.2%
Accounts Payable, Current 6.44M USD +41.2%
Accrued Liabilities, Current 16M USD +138%
Liabilities, Current 93.7M USD +282%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 93.7M USD +279%
Accumulated Other Comprehensive Income (Loss), Net of Tax -22K USD -144%
Retained Earnings (Accumulated Deficit) -525M USD -46.8%
Stockholders' Equity Attributable to Parent 307M USD -28%
Liabilities and Equity 400M USD -11.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -49.7M USD -91.4%
Net Cash Provided by (Used in) Financing Activities 1.18M USD
Net Cash Provided by (Used in) Investing Activities 89.3M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 87.7M shares +0.83%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 240M USD +26.6%
Deferred Tax Assets, Valuation Allowance 94.4M USD +75.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Cash and Cash Equivalents, Period Increase (Decrease) -21.6M USD -119%
Deferred Tax Assets, Gross 94.5M USD +75.1%
Operating Lease, Liability 190K USD -69.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -167M USD -0.8%
Lessee, Operating Lease, Liability, to be Paid 193K USD -70.5%
Property, Plant and Equipment, Gross 243K USD +106%
Operating Lease, Liability, Current 190K USD -55.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 424K USD +2256%
Lessee, Operating Lease, Liability, to be Paid, Year One 424K USD -7.42%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3K USD -91.9%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.63M USD +3.91%
Operating Lease, Payments 1.1M USD
Additional Paid in Capital 832M USD +6.14%
Depreciation, Depletion and Amortization 23K USD +283%
Share-based Payment Arrangement, Expense 46.1M USD +34.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%